IL-2: IL-2RA Inhibitor Screening Colorimetric Assay Kit

Catalog #
78584
$1,095 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The IL-2: IL-2 Receptor Alpha (IL-2RA) Inhibitor Screening Colorimetric Assay Kit is designed for the screening and profiling of inhibitors or neutralizing antibodies blocking the interaction between human IL-2 and its receptor IL-2RA. 

The assay requires only a few steps. First, IL-2RA is coated on a 96-well plate overnight. After blocking, the receptor is pre-incubated with the test inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-IL-2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.

Need us to run inhibitor screens or profile your compounds against IL-2: IL-2RA? Check out our Immunotherapy Biochemical Screening Services.

Product Info
Storage and Usage
Citations
Assay Kit Format
Colorimetric
Supplied As
The kit is provided in a convenient 96-well format, with Biotinylated-IL-2, purified IL-2RA protein, Streptavidin-HRP, and assay buffers for 100 reactions.
Materials Required But Not Supplied
  • PBS (Phosphate buffered saline)
  • 1N HCl (aqueous)           
  • Rotating or rocker platform       
  • UV/Vis spectrophotometer microplate reader capable of reading absorbance at 450 nm
Format
Catalog # Name Amount Storage
101203 IL-2RA, Avi-His Tag* 2 x 10 µg -80°C
101381 IL-2, Fc-Avi-Tag, Biotin-Labeled* 2 x 5 µg -80°C
79311 3x Immuno Buffer 1 50 ml -20°C
79728 Blocking Buffer 2 50 ml +4°C
79742 Streptavidin-HRP 10 µl +4°C
79651 Colorimetric HRP substrate 10 ml +4°C
79964 Transparent 96-well microplate 1 Room Temp

*The initial concentration of both IL-2RA and IL-2 is lot-specific and will be indicated on the tube containing the protein.

UniProt #
IL-2RA: P01589, IL-2: P60568
Background

Interleukin-2 (IL-2) is a cytokine secreted by activated T lymphocytes to stimulate the proliferation of both B and T cells. IL-2 is involved in the extreme inflammation response termed “cytokine storm” observed following viral infection in susceptible patients or following adaptive cell therapy. Thus, it is considered a therapeutic target for the treatment of severe COVID-19.

IL-2 acts by binding to a membrane heterotrimeric receptor consisting of IL-2 receptor alpha (IL2RA, also known as CD25) and beta (IL2RB) chains, which together with the common gamma chain (IL2RG) form a high-affinity receptor, whereas IL-2RA homodimers form a low-affinity receptor. Polymorphisms in the genes coding for IL2RA and IL2RB may be associated with risk of lung cancer.